Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 4, 2003 (Six months ended July 4, 2003)
Business Overview: STAAR Surgical develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, primarily in the cataract, refractive, and glaucoma sectors. Key products include the Implantable Contact Lens (ICL), silicone intraocular lenses (IOLs), and the AquaFlow device. The company operates manufacturing sites in the United States and Switzerland and sells in over 39 countries.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended July 4, 2003 | Six Months Ended June 28, 2002 |
|---|---|---|
| Total Revenues | $25,777 | $23,819 |
| Gross Profit | $14,035 | $11,736 |
| Gross Margin | 54.4% | 49.3% |
| Operating Loss | $(1,602) | $(4,744) |
| Net Loss | $(1,863) | $(4,906) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.29) |
| Cash and Cash Equivalents (End of Period) | $8,414 | $615 |
| Notes Payable (Current) | $3,063 | $5,845 |
| Working Capital | $17,504 | $7,095 |
Liquidity: The company reported a current ratio of 2.4:1 as of July 4, 2003, up from 1.5:1 at the beginning of the year. Cash increased by approximately $7.4 million during the period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 8.2% year-over-year to $25.8 million. This was driven by a 42% increase in international sales of the ICL and a 10.8% increase in specialty lenses (Toric silicone IOL and Collamer IOL).
- Margin Expansion: Gross profit margin improved to 54.4% from 49.3%, attributed to reduced manufacturing costs, improved yields, and a higher mix of high-margin ICL sales.
- Expense Management: Operating loss narrowed significantly to $1.6 million from $4.7 million. Selling, general, and administrative expenses decreased as a percentage of revenue, while R&D expenses increased to 9.9% of revenue due to FDA filing costs for the ICL.
- Product Performance: Sales of the AquaFlow device decreased 16% due to resource diversion toward ICL FDA preparation and injection system troubleshooting. Single-piece silicone IOL sales volume dropped 30% in the U.S. due to delivery system issues.
- Debt Reduction: The company paid off and cancelled its $3.0 million domestic line of credit during the quarter. International subsidiary debt remained at approximately $3.1 million.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- ICL Approval: The company submitted the final module of its Pre-Market Approval (PMA) for the ICL to the FDA in May 2003, receiving expedited review status in July 2003. Management views FDA approval and a successful U.S. launch as critical to future profitability.
- U.S. IOL Recovery: The company expects U.S. IOL sales to increase in the second half of 2003 as delivery system issues are resolved.
- Capital Resources: Liquidity was bolstered by a private placement of common stock raising approximately $9.0 million in June 2003. Management believes current cash and operating cash flow are sufficient to fund operations and growth plans in the near term.
- Regulatory Risk: Failure to obtain FDA approval for the ICL or significant delays would severely diminish prospects for success.
- Market Competition: The company faces competition from larger firms (e.g., Alcon, Bausch & Lomb) and has lost market share in silicone IOLs to acrylic alternatives.
- Product Recalls: History of voluntary recalls (e.g., Collamer lens, silicone lenses) has impacted revenue and reputation; future recalls remain a risk.
- Single-Source Manufacturing: Most products are approved for manufacturing at only one site (U.S. or Switzerland), creating business interruption risks.
- Foreign Currency: Approximately 55% of revenue is international. A stronger U.S. dollar negatively impacts reported sales and gross profit.
Investor Verification Checklist
- ICL FDA Status: Verify the current status of the Pre-Market Approval submission and any potential delays in the expedited review process.
- U.S. IOL Delivery System: Confirm the resolution of delivery system issues affecting single-piece silicone IOL sales and the timeline for volume recovery.
- Private Placement Proceeds: Review the utilization of the $9.0 million raised in June 2003 to ensure it is being deployed as intended for operations and debt reduction.
- International Debt Covenants: Monitor compliance with financial covenants on the Swiss and German subsidiary credit facilities, given the company's history of covenant waivers.
- Days Sales Outstanding (DSO): Track DSO trends (currently 49 days) to ensure extended credit terms to international customers do not strain working capital.